Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin + Toripalimab vs Gemcitabine + Cisplatin in Neoadjuvant MIBC
NCT07647289Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, toripalimab in muscle-invasive bladder cancer (MIBC), sponsored by Peking University Third Hospital. Started Apr 2025; status: recruiting.
02
Drugs
enfortumab vedotintoripalimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07647289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647289.